Drug Trial Radar · NCT06754605
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine
Last checked: Nov 19, 2026Latest source record: Feb 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
480
Planned (sponsor's estimate)
Start
Feb 6, 2025
Primary completion
Jul 30, 2027
Study completion Jul 30, 2027
Sponsor
- Lead sponsor
- Sinocelltech Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomised, double-blind, placebo-controlled Phase 1/2 clinical trial to evaluate the safety, tolerability and immunogenicity of recombinant respiratory syncytial virus in participants aged 18 years and older.
Conditions
- Respiratory Syncytial Virus
Interventions
SCTV02Biological
Participants will receive a singe dose of SCTV02 on Day 0.
PlaceboBiological
Participants will receive a singe dose of Placebo on Day 0.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of solicited adverse events within 7 days post study vaccination.Time frame: Day o to Day 7
- Geometric mean titer (GMT) of neutralizing antibodies (nAb) against RSV-A and RSV-B subtypes 30 days post vaccinationTime frame: Day 30
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hebei Zhongshiyou Central Hospital
Langfang, Hebei, China · Recruiting
Luzhou Center for Disease Control and Prevention
Luzhou, Sichuan, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.